Publication | Closed Access

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Breast OncologyMedicinePrimary AnalysisAdjuvant TreatmentBreast CancerSubcutaneous TrastuzumabDermatologyCancer TreatmentOncologyRadiation Oncology